Definitive Cefmetazole Therapy for Pediatric ESBL-producing Enterobacterales Bacteremia

Abstract

<jats:sec> <jats:title/> <jats:p>This retrospective study evaluated clinical outcomes of cefmetazole, a cephamycin, compared with carbapenems as definitive therapy for pediatric bacteremia caused by extended-spectrum β-lactamase-producing Enterobacterales. Among 43 patients, outcomes with cefmetazole (n = 17) were comparable to those with meropenem (n = 26), including 30-day mortality and recurrence. Cefmetazole may be a carbapenem-sparing option for pediatric extended-spectrum β-lactamase-producing Enterobacterales bacteremia.</jats:p> </jats:sec>